

Resource Summary Report

Generated by SPARC SAWG on Aug 8, 2026

IFPMA - International Federation of Pharmaceutical Manufacturers and Associations

RRID:SCR_012754

Type: Tool

Proper Citation

IFPMA - International Federation of Pharmaceutical Manufacturers and Associations
(RRID:SCR_012754)

Resource Information

URL: <http://ifpma.org/>

Proper Citation: IFPMA - International Federation of Pharmaceutical Manufacturers and Associations (RRID:SCR_012754)

Description: The International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) facilitates dialogue and mutual understanding between the research-based pharmaceutical industry and other global health stakeholders. Our objective is to build trust and help to find broadly supported solutions to the huge and complex issues facing society in the arena of human health. The IFPMA was founded in 1968 as a global, non-profit, non-governmental organization. With members across the world and a secretariat based in Geneva, Switzerland, the IFPMA represents the research-based pharmaceutical industry, including the biotechnology and vaccine sectors. Our members comprise leading international companies as well as national and regional industry associations, in both developed and developing countries, across all five continents. Our primary role is to represent our members' views in dialogue with global intergovernmental organizations, the diplomatic missions of national governments and specialized non-governmental organizations. The IFPMA advocates policies that encourage discovery of and access to life-saving and life-enhancing new medicines to improve the health of patients everywhere. To fulfill its mission, the IFPMA has established a number of key guiding principles: * To encourage a global policy environment that is conducive to innovation in medicine, both therapeutic and preventive, for the benefit of patients around the world; * To promote and support principles of ethical conduct and practices voluntarily agreed upon, as exemplified by the IFPMA Code of Pharmaceutical Marketing Practices; * To promote and support the adoption of high standards of manufacturing practices and quality assurance for pharmaceutical products; * To contribute industry expertise and foster collaborative relationships and partnerships with international organizations that are dedicated to the improvement of public health, especially in developing and emerging countries; and * To assure regular contact and

experience-sharing and coordinate the efforts of its members towards achieving these objectives.

Abbreviations: IFPMA

Synonyms: International Federation of Pharmaceutical Manufacturers and Associations

Resource Type: knowledge environment, data or information resource, portal, organization portal

Keywords: research and development, pharmaceutical industry, biotech, vaccine, pharmaceutical, biotechnology

Resource Name: IFPMA - International Federation of Pharmaceutical Manufacturers and Associations

Resource ID: SCR_012754

Alternate IDs: nlx_21353

Record Creation Time: 20220129T080312+0000

Record Last Update: 20260808T190311+0000

Ratings and Alerts

No rating or validation information has been found for IFPMA - International Federation of Pharmaceutical Manufacturers and Associations.

No alerts have been found for IFPMA - International Federation of Pharmaceutical Manufacturers and Associations.

Data and Source Information

Source: [SciCrunch Registry](#)

Usage and Citation Metrics

We found 6 mentions in open access literature.

Listed below are recent publications. The full list is available at [SPARC SAWG](#) .

Pagliusi S, et al. (2020) Two decades of vaccine innovations for global public good: Report of the Developing Countries' Vaccine Manufacturers Network 20th meeting, 21-23 october 2019, Rio de Janeiro, Brazil. Vaccine, 38(36), 5851.

Bataglia W, et al. (2020) [Comparative analysis of policies regulating clinical trialsAnálisis comparativo de las políticas de reglamentación de los ensayos clínicos]. Revista panamericana de salud publica = Pan American journal of public health, 44, e3.

Potthast R, et al. (2014) Impact of inclusion of industry trial results registries as an information source for systematic reviews. PloS one, 9(4), e92067.

Li L, et al. (2014) Systematic Review of Chinese Medicine for Miscarriage during Early Pregnancy. Evidence-based complementary and alternative medicine : eCAM, 2014, 753856.

Francer J, et al. (2014) Ethical pharmaceutical promotion and communications worldwide: codes and regulations. Philosophy, ethics, and humanities in medicine : PEHM, 9, 7.

Wittes J, et al. (2001) Experience collecting interim data on mortality: an example from the RALES study. Current controlled trials in cardiovascular medicine, 2(1), 59.